Literature DB >> 29437945

A comparison of linezolid lung tissue concentrations among patients with drug-resistant tuberculosis.

Russell R Kempker1, M Tobias Heinrichs2, Ketino Nikolaishvili3, Irina Sabulua3, Nino Bablishvili3, Shota Gogishvili3, Zaza Avaliani3, Brent P Little4, Adam Bernheim4, Hartmut Derendorf2, Henry M Blumberg5,6, Sergo Vashakidze3, Charles A Peloquin2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29437945      PMCID： PMC6223612          DOI： 10.1183/13993003.02166-2017

Source DB:  PubMed          Journal:  Eur Respir J        ISSN： 0903-1936            Impact factor:   16.671


× No keyword cloud information.
  12 in total

1.  Additional drug resistance in Mycobacterium tuberculosis isolates from resected cavities among patients with multidrug-resistant or extensively drug-resistant pulmonary tuberculosis.

Authors:  Russell R Kempker; Alexander S Rabin; Ketino Nikolaishvili; Iagor Kalandadze; Shota Gogishvili; Henry M Blumberg; Sergo Vashakidze
Journal:  Clin Infect Dis       Date:  2011-12-23       Impact factor: 9.079

2.  Pharmacokinetics and intrapulmonary concentrations of linezolid administered to critically ill patients with ventilator-associated pneumonia.

Authors:  Emmanuel Boselli; Dominique Breilh; Thomas Rimmelé; Sarah Djabarouti; Jérôme Toutain; Dominique Chassard; Marie-Claude Saux; Bernard Allaouchiche
Journal:  Crit Care Med       Date:  2005-07       Impact factor: 7.598

3.  Lung Tissue Concentrations of Pyrazinamide among Patients with Drug-Resistant Pulmonary Tuberculosis.

Authors:  Russell R Kempker; M Tobias Heinrichs; Ketino Nikolaishvili; Irina Sabulua; Nino Bablishvili; Shota Gogishvili; Zaza Avaliani; Nestani Tukvadze; Brent Little; Adam Bernheim; Timothy D Read; Jeannette Guarner; Hartmut Derendorf; Charles A Peloquin; Henry M Blumberg; Sergo Vashakidze
Journal:  Antimicrob Agents Chemother       Date:  2017-05-24       Impact factor: 5.191

4.  Intrapulmonary pharmacokinetics of linezolid.

Authors:  John E Conte; Jeffrey A Golden; Juliana Kipps; Elisabeth Zurlinden
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

Review 5.  Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis.

Authors:  Giovanni Sotgiu; Rosella Centis; Lia D'Ambrosio; Jan-William C Alffenaar; Holly A Anger; Jose A Caminero; Paolo Castiglia; Saverio De Lorenzo; Giovanni Ferrara; Won-Jung Koh; Giesela F Schecter; Tae S Shim; Rupak Singla; Alena Skrahina; Antonio Spanevello; Zarir F Udwadia; Miquel Villar; Elisabetta Zampogna; Jean-Pierre Zellweger; Alimuddin Zumla; Giovanni Battista Migliori
Journal:  Eur Respir J       Date:  2012-04-10       Impact factor: 16.671

6.  Cavitary penetration of levofloxacin among patients with multidrug-resistant tuberculosis.

Authors:  Russell R Kempker; Aline B Barth; Sergo Vashakidze; Ketino Nikolaishvili; Irina Sabulua; Nestani Tukvadze; Nino Bablishvili; Shota Gogishvili; Ravi Shankar P Singh; Jeannette Guarner; Hartmut Derendorf; Charles A Peloquin; Henry M Blumberg
Journal:  Antimicrob Agents Chemother       Date:  2015-03-16       Impact factor: 5.191

7.  Wild-type distributions of seven oral second-line drugs against Mycobacterium tuberculosis.

Authors:  T Schön; P Juréen; E Chryssanthou; C G Giske; E Sturegård; G Kahlmeter; S Hoffner; K A Angeby
Journal:  Int J Tuberc Lung Dis       Date:  2011-04       Impact factor: 2.373

8.  Intrapulmonary penetration of linezolid.

Authors:  David Honeybourne; Caroline Tobin; Gail Jevons; Jenny Andrews; Richard Wise
Journal:  J Antimicrob Chemother       Date:  2003-05-13       Impact factor: 5.790

9.  Mutant prevention concentration: comparison of fluoroquinolones and linezolid with Mycobacterium tuberculosis.

Authors:  J C Rodríguez; L Cebrián; M López; M Ruiz; I Jiménez; G Royo
Journal:  J Antimicrob Chemother       Date:  2004-02-12       Impact factor: 5.790

10.  Linezolid Dose That Maximizes Sterilizing Effect While Minimizing Toxicity and Resistance Emergence for Tuberculosis.

Authors:  Shashikant Srivastava; Gesham Magombedze; Thearith Koeuth; Carleton Sherman; Jotam G Pasipanodya; Prithvi Raj; Edward Wakeland; Devyani Deshpande; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191
View more
  4 in total

1.  Distribution of Linezolid in Tuberculosis Lesions in Patients with Spinal Multidrug-Resistant Tuberculosis.

Authors:  Yuan Li; Weijie Dong; Tinglong Lan; Jun Fan; Shibing Qin; Ai Guo
Journal:  Antimicrob Agents Chemother       Date:  2020-06-23       Impact factor: 5.191

Review 2.  Model-Informed Drug Development for Anti-Infectives: State of the Art and Future.

Authors:  Craig R Rayner; Patrick F Smith; David Andes; Kayla Andrews; Hartmut Derendorf; Lena E Friberg; Debra Hanna; Alex Lepak; Edward Mills; Thomas M Polasek; Jason A Roberts; Virna Schuck; Mark J Shelton; David Wesche; Karen Rowland-Yeo
Journal:  Clin Pharmacol Ther       Date:  2021-03-09       Impact factor: 6.875

Review 3.  Linezolid-induced pure red cell aplasia: a case report and literature review.

Authors:  Zhuanbo Luo; Ning Xu; Yun Wang; Xiaoping Huang; Chao Cao; Lei Chen
Journal:  J Int Med Res       Date:  2018-10-01       Impact factor: 1.671

4.  Penetration of linezolid into bone tissue 24 h after administration in patients with multidrug-resistant spinal tuberculosis.

Authors:  Yuan Li; Hairong Huang; Weijie Dong; Tinglong Lan; Jun Fan; Shu'an Wen; Tingting Zhang; Shibing Qin; Ai Guo
Journal:  PLoS One       Date:  2019-10-03       Impact factor: 3.240
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.